Fargnoli, Maria Concetta http://orcid.org/0000-0002-7249-2556
De Simone, Clara
Gisondi, Paolo
Pellacani, Giovanni
Calzavara-Pinton, Piergiacomo
Funding for this research was provided by:
LEO Pharma
Article History
Received: 23 May 2023
Accepted: 30 August 2023
First Online: 22 September 2023
Declarations
:
: Maria Concetta Fargnoli has served on advisory boards, received honoraria for lectures and research grants from AMGEN, Almirall, Abbvie, Leo Pharma, Janssen, Lilly, Novartis, Pfizer and UCB. Clara De Simone has served as a speaker, consultant or advisory board member and has received honoraria from Abbvie, Almirall,Amgen, Eli Lilly, Leo Pharma, Janssen, Novartis, and UCB Pharma. Giovanni Pellacani has no conflicts of interest to declare. Paolo Gisondi has served Amgen, Almirall, Abbvie, Leo Pharma, Eli Lilly, Pfizer, Janssen, Novartis, UCB for advisory boards and/or lectures. Piergiacomo Calzavara-Pinton has served as a speaker, consultant or advisory board member and has received honoraria from Galderma, Pierre-Fabre, Incyte, Almirall, Abbvie, Leo Pharma, UCB, Lilly, Pfizer, Janssen, Cantabria, Molteni and Novartis.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.